Day 3 Embryo Biopsy Versus Blastocyst Biopsy in PGS Cases
NCT ID: NCT01950104
Last Updated: 2020-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2015-08-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
At present, it has not been proved that the usage of PGS really improves the live birth rate in IVF cycles. However, it has been stated that the reason of not having better results when using PGS is that the methodology applied is not adequate.
Several authors propose that the optimal methodology for PGS includes the application of comparative genomic hybridization (CGH) arrays for genetic testing and carrying out embryo biopsy at the blastocyst stage. Nevertheless, most IVF centres still applies the day 3 embryo biopsy as a daily routine. Despite this fact, there is a gradual transition towards the usage of blastocyst-stage biopsy instead of day 3 biopsy.
The purpose of this clinical study is analysing the results of the IVF cycles with embryo biopsy for PGS. Live birth rates and other parameters as the pregnancy and implantation rates together with embryo quality will be analysed and compared between two groups of patients undergoing IVF cycles with PGS. In one group the biopsy will be applied in day 3 of the embryo development, while in the other group the embryo biopsy will be fulfilled at the blastocyst stage.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preimplantation Genetic Screening (PGS) in Advanced Female Age and Male Severe Factor
NCT01571076
The Transition From Blastomere to Trophectoderm Biopsy: Comparing Two PGS Strategies
NCT03062969
Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age
NCT00646893
Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy
NCT01332643
Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH
NCT01546350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Day 3 embryo biopsy
Embryo biopsy is applied at day 3 of the embryo development
Day 3 embryo biopsy
Embryo biopsy is applied at day 3 of the embryo development.
Blastocyst biopsy
Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
Blastocyst biopsy
Embryo biopsy is applied at the blastocyst stage of the embryo development
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Day 3 embryo biopsy
Embryo biopsy is applied at day 3 of the embryo development.
Blastocyst biopsy
Embryo biopsy is applied at the blastocyst stage of the embryo development
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Advanced maternal age
* Recurrent implantation failure
* Recurrent abortion
* Severe male-factor infertility
Exclusion Criteria
* Patients undergoing preimplantation genetic diagnosis
18 Years
49 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vida Recoletas Sevilla
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IVI Sevilla
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IVISEV-005VINCI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.